K

Kyowa Kirin

Global specialty pharma focused on antibodies

Data Scientist

Full-Time
$160.4k - $192.8k/yr+ Annual Bonus Program + Long Term Incentive Program
Expert
Bachelor's, Master's, PhD
Princeton, NJ, USA
In PersonRequires up to 5% domestic and international travel.
Data & AnalyticsData Science

About the job

Requirements
  • A bachelor's degree in Statistics, Computer Science, Economics, Applied Mathematics, or a related field is required.
  • At least 10 years of relevant experience, including data science, advanced statistics, and business analysis, is required.
  • Strong understanding of healthcare data and technology is required.
  • Strong quantitative and diverse analytical skills, including exploratory data analysis, computer science, statistics, modeling, mathematics, programming languages, and business acumen, are required.
  • Extensive experience working with large, complex data and proficiency in SAS, R, Python, or SQL, plus experience with big data technologies such as Hadoop, is required.
  • Experience with querying, algorithms, data engineering, natural language processing, recommendation engines, experimentation, programming, data storytelling and intelligence, predictive modeling, and machine learning is required.
  • Strong knowledge of secondary data sources, including syndicated sales, promotional and marketing data, longitudinal patient-level data, diagnostic laboratory data, and payer data, is required.
  • Proficiency in manipulating and extracting insights from large longitudinal data sources, such as claims, diagnostic, electronic medical record, and other datasets, is required.
  • Expertise in managing and analyzing a range of large secondary transactional databases is required.
  • Experience with field force analytics, including customer segmentation, targeting, and promotional response measurement, is required.
  • Competency in navigating large volumes of information to synthesize important and actionable findings is required.
  • Strong organizational skills and time management are required to manage a diverse range of projects simultaneously.
  • Strong interpersonal and communication skills and a consultative mindset are required to develop partnerships and influence without authority.
  • Clear oral and written communication skills are required, including the ability to describe complex data topics in simple terms.
  • Proficiency in Python, R, SQL, and SAS is required.
  • A strong foundation in statistical analysis, modeling, and quantitative research is required.
  • Experience with visualization tools such as Tableau and Power BI, big data platforms such as Hadoop and Spark, and the Microsoft Office suite is required.
  • The ability to organize, prioritize, meet deadlines, make decisions, and change course quickly is required.
  • A strong work ethic, attention to detail, follow-through, flexibility, ability to deal with ambiguity, cultural sensitivity, and ability to develop consensus within a multinational organization are required.
Responsibilities
  • Identify opportunities for machine learning and business intelligence to solve unmet medical needs and support data analysis for market insights.
  • Create artificial intelligence and machine learning infrastructure to support key strategic initiatives.
  • Implement advanced analytics for commercial teams, including exploratory applications of machine learning, deep learning, and artificial intelligence.
  • Enhance intelligence systems and predictive analytical techniques to influence strategic business decisions and address business objectives.
  • Leverage advanced data integration and governance capabilities through cloud computing and artificial intelligence and machine learning.
  • Use machine learning to build predictive models for commercial initiatives.
  • Develop automated capabilities that enable machine learning across the company's portfolio of medicines.
  • Build and fine-tune algorithms that scale from proof-of-concept to full production systems in a timely manner.
  • Communicate complex findings and insights to technical and non-technical stakeholders through data visualizations, reports, and presentations.
  • Collaborate with peers in other functions on cross-functional analytics projects and solutions.
Desired Qualifications
  • A master's or Ph.D. degree is preferred.
  • Cross-industry experience in pharmaceutical, consumer, or technology industries is preferred.

About the company

1) What does this company do? Kyowa Kirin develops specialty pharmaceutical drugs with a focus on nephrology, oncology, and immunology, built on a foundation of fermentation technology and antibody science. 2) How does this company's product(s) work? It uses fermentation-derived biology and antibody-based approaches to create therapies that target kidney disease, cancer, and immune-related conditions, delivered as approved medicines after research, development, and clinical testing. 3) How is this company different from its competitors? It blends deep fermentation and microbiology expertise with antibody technology from its history, plus a global specialty-drug focus, resulting from a merger of Kyowa Hakko Kogyo and Kirin Pharma that combined fermentation know-how with pharmaceutical resources. 4) What is this company's goal? To develop and commercialize innovative treatments that address unmet medical needs in nephrology, oncology, and immunology on a global scale.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1885

Get referred to Kyowa Kirin

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA selected Sanford for its PreCheck Pilot Program on June 30, 2026.
  • Kyowa Kirin signed a U.S. access deal August 31, 2026, deferring Section 232 tariffs.
  • Pipeline remains active: KHK4951, OTL-203, and ziftomenib all advanced in 2026.

What critics are saying

  • Rocatinlimab died March 3, 2026 after Kaposi's sarcoma signals and trial termination.
  • Kyowa Kirin faces patent cliffs: major products lose protection in 2032 and 2033.
  • Sanford's $530 million build concentrates execution risk until FDA-ready production starts in 2027.

What makes Kyowa Kirin unique

  • Kyowa Kirin owns antibody, fermentation, and rare-disease manufacturing expertise since 1949.
  • The Sanford, North Carolina plant becomes its first U.S. biologics site, operational 2027.
  • Ziftomenib outside the U.S. gives Kyowa Kirin global AML rights through 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Unlimited Paid Time Off
  • Hybrid Work Options
  • Pet Insurance

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

-2%
Yahoo Finance
Aug 26th, 2026
Cognizant wins Kyowa Kirin AI R&D deal to implement Benchling platform in Japan

Cognizant Technology Solutions will support Kyowa Kirin in implementing Benchling, an AI-driven R&D platform, at the Tokyo and Fuji Research Parks in Japan. The engagement includes platform setup, data migration, ongoing maintenance, and workflow optimization for drug discovery research. The deal reinforces Cognizant's enterprise-scale AI automation capabilities in life sciences digitalization. However, it is unlikely to shift near-term catalysts around broader AI adoption or risks that AI may erode demand for labour-intensive services. Cognizant's narrative projects $24.9 billion revenue and $3.1 billion earnings by 2029, requiring 5.2% yearly revenue growth. The most optimistic analysts forecast revenue reaching $26.1 billion and earnings of $3.9 billion by 2029, depending on how AI investments translate into higher-margin work.

IT Business Today
Aug 17th, 2026
Kyowa Kirin modernizes with Cognizant and Benchling R&D with AI and automation.

Kyowa Kirin modernizes with Cognizant and Benchling R&D with AI and automation. Last updated: August 17, 2026 12:53 pm Kyowa Kirin has chosen Cognizant and Benchling to support the rollout of Benchling's cloud-based R&D platform at its Tokyo Research Park and Fuji Research Park. The platform brings experimental planning, data collection, AI tools, and workflow automation into one place. Researchers can connect experimental equipment directly to Benchling, allowing data to be captured as structured and searchable records instead of being entered manually. That matters as Kyowa Kirin's research work becomes more complex and its pipeline expands. The company expects the platform to help speed up activities ranging from identifying drug targets to selecting new drug candidates. Researchers will also be able to search past experiments, generate reports, examine relationships between studies, and support molecular design using the platform's analytical and AI capabilities. Cognizant will handle the implementation using Benchling, including platform setup, data migration, deployment, and the ongoing upkeep too. This partnership shows where pharma research and development is headed, more or less, these days. More of the work around data handling and routine processes is being moved into connected digital systems, while AI is being brought closer to the research itself rather than treated as a separate tool. ITBT Staffwriter is an in-house contributor at IT Business Today, responsible for delivering timely News and QuickBytes. The author covers the latest developments across IT, tech, and enterprise solutions to keep readers informed with concise and impactful updates. August 17, 2026

Benzinga
Dec 15th, 2025
Link Cell Therapies raises $92M to advance CAR-T cancer treatments for solid and liquid tumors

Link Cell Therapies has emerged from stealth with $60 million in Series A funding led by Johnson & Johnson Innovation – JJDC, bringing total capital raised to $92 million. The South San Francisco–based oncology company is developing CAR-T therapies for solid and liquid tumours using proprietary logic-gating technology. The platform enables safe targeting of multiple antigens co-expressed on cancer cells whilst sparing healthy tissue. Co-founded by Dr Robbie Majzner and Dr Crystal Mackall at Stanford University in 2022, Link's lead programme, LNK001 for renal cell carcinoma, is on track for an IND application and Phase I trial in 2026. The Series A round included participation from founding investors Samsara BioCapital and Sheatree Capital, alongside new backers Bristol Myers Squibb, Kyowa Kirin and Wing Venture Capital.

PR Newswire
Dec 15th, 2025
Link Cell Therapies Launches with Vision of Advancing CAR-T Therapies in Solid and Liquid Tumors

/PRNewswire/ -- Link Cell Therapies ("Link"), an oncology cell therapy company, today announced its official launch from stealth with a $60 million Series A...

FinSMEs
Mar 4th, 2025
Garuda Therapeutics Closes $50M Series A-1 Financing

Garuda Therapeutics, a Cambridge, MA-based hematopoietic stem cell (HSC) therapies company, raised $50M in Series A-1 funding